<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>College of Medical, Veterinary &amp;Life Sci</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/EC383F65-8919-45C4-AF30-4076C5F55E90"><gtr:id>EC383F65-8919-45C4-AF30-4076C5F55E90</gtr:id><gtr:firstName>Kennedy</gtr:firstName><gtr:surname>Lees</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0200583"><gtr:id>07602674-4C10-48DA-87E1-BAEB4887C56D</gtr:id><gtr:title>VITATOPS study: A randomised, double-blind, placebo-controlled trial of VITAmins TO Prevent Stroke - Extension</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0200583</gtr:grantReference><gtr:abstractText>It was recently discovered that high levels of a substance called homocysteine (pronounced `home-o-sis-teen`) in the blood can damage the lining of blood vessels, causing `hardening of the arteries` (atherosclerosis). This eventually causes them to become completely blocked. When such a blockage occurs in the brain, there is poor supply of oxygen to the brain causing a stroke. However, homocysteine levels can be effectively lowered using vitamins, which means we may be able to prevent stroke by taking vitamins. As yet, no one has proven that vitamin treatment prevents stroke and other forms of blood vessel disease. The VITATOPS study has been designed to answer this question. 
VITATOPS is an international study designed to determine whether or not vitamins prevent stroke and other forms of blood vessel disease. People who have had a stroke are treated daily with either a multi-vitamin tablet or a placebo (a ?dummy? tablet). At the end of the study patients taking vitamins will be compared with those taking the placebo to determine whether vitamin treatment is beneficial or not. 
We intend to extend the study, recruiting approximately 1500 patients instead of the 750 patients for whom we already have funding. All of our patients will also be kept under observation for an extra two years. This will enable sufficient numbers to be obtained to be able to determine whether vitamins prevent stroke and other vascular events.</gtr:abstractText><gtr:technicalSummary>This proposal is to extend MRC funding of the VITATOPS RCT to mid 2010. 

There is a large body of consistent, biologically plausible, epidemiological evidence linking hyperhomocysteinaemia (HHC) in a dose-dependent fashion to an increased risk of atherosclerotic vascular morbidity and mortality. Furthermore, HHC is being associated increasingly with an increased risk of vascular dementia, dementia of Alzheimer type, and depression. A simple, non-toxic, and inexpensive therapeutic intervention in the form of multi-vitamins (folate, B6, B12) has been shown to be highly effective at reducing plasma homocysteine (Hcy) levels, irrespective of the underlying cause. However, the efficacy of Hcy-lowering therapy in reducing vascular injury, and the impact which this may have on vascular morbidity and mortality, dementia and depression remains to be demonstrated. The VITATOPS study is an international multi-centre, randomized, double-blind, placebo-controlled, clinical trial designed primarily to examine the efficacy and safety of multivitamin (folate, B6, B12) therapy in the prevention of ?stroke, myocardial infarction, or death from any vascular cause?, among patients randomized within seven months of a stroke or transient ischaemic attack (TIA) of the eye or brain. Secondary outcomes include TIA, dementia, depression unstable angina and revascularization procedures of the coronary, cerebral and peripheral circulations. We plan that 8,000 patients will be randomized and followed up. The trial is designed to detect a relative risk reduction of 15% in the vitamin treated group, with a power of 80% (a=0.05).

Worldwide, recruitment to the trial has been extended until June 2008 to compensate for a slower worldwide recruitment and low primary outcome rate than anticipated. Follow-up has been extended to June 2010. Recruitment in the UK remains excellent, with a total of 950 patients recruited to November 2005. The original MRC grant covers recruitment, follow-up and monitoring costs for 750 patients for the UK and until June 2006. This effectively means that recruitment and follow up in the UK would cease at this point, with a loss of many more potential patients and important follow-up information. We estimate that at the present rate we could recruit 1500 patients in total and the proposed grant application seeks funding to cover the difference between the original 750 patients and the estimate of 1500, as well as the extended duration of the trial.</gtr:technicalSummary><gtr:fund><gtr:end>2010-07-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2003-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>893231</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Patient participant meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>5836404A-6C53-4EAB-AEC4-AC52A8C56F61</gtr:id><gtr:impact>Approx 100 participants attended for presentation and discussion. Also, every particpant received letter. results also disseminated via website of SRN.

Not applicable.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DC6FAD79-AD96-4387-AB98-DF440B9EAC9F"><gtr:id>DC6FAD79-AD96-4387-AB98-DF440B9EAC9F</gtr:id><gtr:title>Frequent early cardiac complications contribute to worse stroke outcome in atrial fibrillation.</gtr:title><gtr:parentPublicationTitle>Cerebrovascular diseases (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b421bdd69ec817ce3389263b8747ba78"><gtr:id>b421bdd69ec817ce3389263b8747ba78</gtr:id><gtr:otherNames>Tu HT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1015-9770</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B0FCD04D-FA7E-49EE-869A-1BC85F8CDDAC"><gtr:id>B0FCD04D-FA7E-49EE-869A-1BC85F8CDDAC</gtr:id><gtr:title>B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8206256ce34b1e0ae407c7c82c8f9cb3"><gtr:id>8206256ce34b1e0ae407c7c82c8f9cb3</gtr:id><gtr:otherNames>VITATOPS Trial Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A369DA1F-FEE8-4B1A-BBBA-3B888DE4B124"><gtr:id>A369DA1F-FEE8-4B1A-BBBA-3B888DE4B124</gtr:id><gtr:title>Treatment with B vitamins and incidence of cancer in patients with previous stroke or transient ischemic attack: results of a randomized placebo-controlled trial.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5428d0a2a4dadad12b13976ca900c32a"><gtr:id>5428d0a2a4dadad12b13976ca900c32a</gtr:id><gtr:otherNames>Hankey GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/695C07A5-D224-4EC6-9C56-DA7CFAE7D62A"><gtr:id>695C07A5-D224-4EC6-9C56-DA7CFAE7D62A</gtr:id><gtr:title>Effect of B vitamins and lowering homocysteine on cognitive impairment in patients with previous stroke or transient ischemic attack: a prespecified secondary analysis of a randomized, placebo-controlled trial and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5428d0a2a4dadad12b13976ca900c32a"><gtr:id>5428d0a2a4dadad12b13976ca900c32a</gtr:id><gtr:otherNames>Hankey GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A134569F-A025-4BB9-A483-0113772566E6"><gtr:id>A134569F-A025-4BB9-A483-0113772566E6</gtr:id><gtr:title>Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5428d0a2a4dadad12b13976ca900c32a"><gtr:id>5428d0a2a4dadad12b13976ca900c32a</gtr:id><gtr:otherNames>Hankey GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5A350FB7-AEE8-4BE9-9CCD-B2E76AAACF80"><gtr:id>5A350FB7-AEE8-4BE9-9CCD-B2E76AAACF80</gtr:id><gtr:title>VITATOPS, the VITAmins TO prevent stroke trial: rationale and design of a randomised trial of B-vitamin therapy in patients with recent transient ischaemic attack or stroke (NCT00097669) (ISRCTN74743444).</gtr:title><gtr:parentPublicationTitle>International journal of stroke : official journal of the International Stroke Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8206256ce34b1e0ae407c7c82c8f9cb3"><gtr:id>8206256ce34b1e0ae407c7c82c8f9cb3</gtr:id><gtr:otherNames>VITATOPS Trial Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1747-4930</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0200583</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>A77DAE3A-499B-4F46-971D-6C82F51F9C2E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Stroke</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>